The APE1/REF-1 and the hallmarks of cancer-Reference-Cited by-同舟云学术

The APE1/REF-1 and the hallmarks of cancer

Published:2024-01-02 Issue:1 Volume:51 Page:
ISSN:0301-4851
Container-title:Molecular Biology Reports
language:en
Short-container-title:Mol Biol Rep

Author:

Siqueira Priscyanne Barreto^ORCID,de Sousa Rodrigues Mariana Moreno^ORCID,de Amorim Ísis Salviano Soares^ORCID,da Silva Thayssa Gomes^ORCID,da Silva Oliveira Matheus^ORCID,Rodrigues Juliana Alves^ORCID,de Souza da Fonseca Adenilson^ORCID,Mencalha Andre Luiz^ORCID

Funder

Conselho Nacional de Desenvolvimento Científico e Tecnológico

Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s11033-023-08946-9.pdf

Reference105 articles.

1. Whitaker AM, Freudenthal BD (2018) APE1: a skilled nucleic acid surgeon. DNA Repair (Amst) 71:93–100. https://doi.org/10.1016/j.dnarep.2018.08.012

2. Abbotts R, Madhusudan S (2010) Human AP endonuclease 1 (APE1): from mechanistic insights to druggable target in cancer. Cancer Treat Rev 36:425–435. https://doi.org/10.1016/j.ctrv.2009.12.006

3. Choi S, Joo HK, Jeon BH (2016) Dynamic regulation of APE1/Ref-1 as a therapeutic target protein. Chonnam Med J 52:75. https://doi.org/10.4068/cmj.2016.52.2.75

4. Liu Y, Zhang Z, Zhang L, Zhong Z (2020) Cytoplasmic APE1 promotes resistance response in osteosarcoma patients with cisplatin treatment. Cell Biochem Funct 38:195–203. https://doi.org/10.1002/cbf.3461